SANUWAVE Health, Inc. (SNWV)
NASDAQ: SNWV · Real-Time Price · USD
16.85
-0.22 (-1.29%)
At close: May 15, 2026, 4:00 PM EDT
16.70
-0.15 (-0.89%)
After-hours: May 15, 2026, 4:37 PM EDT
Company Description
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally.
It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.
The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds.
The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
SANUWAVE Health, Inc.
| Country | United States |
| Founded | 2004 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Morgan Frank |
Contact Details
Address: 9600 W. 76th Street, Suite 118 Eden Prairie, Minnesota 55344 United States | |
| Phone | 952 656 1029 |
| Website | sanuwave.com |
Stock Details
| Ticker Symbol | SNWV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001417663 |
| CUSIP Number | 80303D107 |
| ISIN Number | US80303D3052 |
| Employer ID | 20-1176000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Morgan C. Frank | Chief Executive Officer and Chairman |
| Daniel Coyle | Chief Operating Officer |
| Timothy Wern | Executive Vice President of Sales - U.S. Wound |
| Peter Sorensen | Chief Financial Officer and Secretary |
| Dr. Christopher Cook Ph.D. | Chief Technology Officer |
| Peter Stegagno | Chief Regulatory Officer |
| Dustin Libby | Executive Vice President of Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | 8-K | Current Report |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 4, 2026 | SCHEDULE 13G/A | Filing |
| Apr 29, 2026 | ARS | Filing |
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 16, 2026 | 8-K | Current Report |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |
| Mar 26, 2026 | 8-K | Current Report |
| Mar 26, 2026 | 10-K | Annual Report |